A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proprosals

The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) are soliciting proposals from small business concerns that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward NIH or CDC mission needs and Small Business Innovation Research (SBIR) program objectives.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS), THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) SMALL BUSINESS INNOVATIVE RESEARCH (SBIR) PROGRAM SOLICITATION PHS-2021-1 is anticipated to be made available on or around July 24, 2020, through both beta.SAM.gov and the NIH Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) funding web page at https://sbir.nih.gov/funding.  This solicitation is anticipated to have a closing date of October 26, 2020 for receipt of proposals.

The purposes of the SBIR program are to: (a) stimulate technological innovation; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and (d) increase private sector commercialization of innovations derived from Federal R/R&D, thereby increasing competition, productivity and economic growth.

For purposes of the SBIR program, a small business concern is any business concern that, on the date of award, (1) is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; (2) is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; (3) more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these.  No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern; AND, (4) has, including its affiliates, no more than 500 employees.*

* Note: This size standard is established by law for the SBIR program, regardless of the NAICS Code assigned. See 13 C.F.R. § 121.702.

THE FOLLOWING RESEARCH TOPICS ARE ANTICIPATED TO BE INCLUDED IN SBIR CONTRACT SOLICITATION PHS-2021-1

NATIONAL INSTITUTES OF HEALTH (NIH)

NATIONAL CENTER FOR ADVANCING TRANSLATIONS SCIENCES (NCATS):

Topic 020 - Development of Remote Rare Disease Patient Care Environment through Immersive Virtual Reality

Topic 021 - Platform for Rapidly Deployable Autonomous Laboratory

NATIONAL CANCER INSTITUTE (NCI):

Topic 413 - Next Generation 3D Tissue Culture Systems with Tertiary Lymphoid Organs

Topic 414 - Synthetic Biology Gene Circuits for Cancer Therapy

Topic 415 - Applicator-Compatible Electronic Brachytherapy Sources for Cancer Radiotherapy

Topic 416 - Self-Sampling Devices for HPV-Testing-Based Cervical Cancer Screening

Topic 417 - Quantitative Imaging Software Tools for Cancer Diagnosis and Treatment Planning

Topic 418 - 3D Spatial Omics for Molecular and Cellular Tumor Atlas Construction

Topic 419 - Understanding Cancer Tumor Genomic Results: Technology Applications for Providers

Topic 420 - Single-Cell “Unbiased Discovery” Proteomic Technologies

Topic 421 - Quantitative Biomimetic Phantoms for Cancer Imaging and Radiation Dosimetry

Topic 422 - Spatial Sequencing Technologies with Single Cell Resolution for Cancer Research and Precision Medicine

Topic 423 - Software to Address Social Determinants of Health in Oncology Practices

Topic 424 - Digital Tools to Improve Health Outcomes in Pediatric Cancer Survivors

Topic 425 - Information Technology Tools for Automated Analysis of Physical Activity, Performance, and Behavior from Images for Improved Cancer Health

Topic 426 - Tools and Technologies for Visualizing Multi-Scale Data

Topic 427 - De-Identification Software Tools and Pipelines for Cancer Imaging Research

Topic 428 - Cloud-Based Multi-Omic and Imaging Software for the Cancer Research Data Commons

Topic 429 - Advanced Manufacturing to Speed Availability of Emerging Autologous Cell-Based Therapies

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI): 

Topic 111 - Oxygen Delivery Device Innovations

Topic 112 - Intramyocardial Suture Annuloplasty System (“SCIMITAR” devices)

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID):

Topic 087 - Point-of-Care HIV Viral Load, Drug Resistance, and Adherence Assays

Topic 088 - Therapeutic Targeting of Intracellular HIV-1 Proteins or Nucleic Acids

Topic 089 - Particle-based Co-delivery of HIV immunogens as Next-generation HIV Vaccines

Topic 090 - Sequence-based Assays to Quantify the Replication-Competent HIV Reservoir

Topic 091 - Adjuvant Development for Vaccines and for Autoimmune and Allergic Diseases

Topic 092 - Adjuvant Discovery for Vaccines and for Autoimmune and Allergic Diseases

Topic 093 - Production of Adjuvants Mimics

Topic 094 - Reagents for Immunologic Analysis of Non-mammalian and Underrepresented Mammalian Models

Topic 095 - Improving Technologies to Make Large-scale High Titer Phage Preps

Topic 096 - Development of priority diagnostics for Chagas disease

Topic 097 - Pediatric Formulations of Select Second Line Drugs for Treating Tuberculosis

Topic 098 - Group A Streptococcus Vaccine Development

Topic 099 - Rapid, Point-of-Care Diagnostics for Hepatitis C Virus

Topic 100 - Informatics Tools (Data Science Tools) for Infectious, Immune, and Allergic Research

CENTER FOR DISEASE CONTROL AND PREVENTION (CDC)

CENTER FOR PREPAREDNESS AND RESPONSE (CPR):

Topic 006 - Developing Innovative Specimen Packaging Approaches to Improve Transit Success Rates

NATIONAL CENTER FOR EMERGING ZOONOTIC AND INFECTIOUS DISEASE (NCEZID):

Topic 024 - Device Development for Microbial Surface Sampling, Field Extraction and Collection

Topic 025 - Development of a Diagnostic Testing Platform to Assess Antibiotic Activity on Microbial Communities

Topic 026 - Intradermal Delivery Human Rabies Vaccine Using Dissolvable Microneedles

Topic 027 - Interactive Phone-Based Video Game to Promote Handwashing Behavior Among Children

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP):

Topic 050 - Agnostics Computer Vision Solution for Highly Integrated Robotic Platforms

Topic 051 - Microfluidics for Genetic and Serological Characterization of hepatitis C Virus Infection

NOTE – SBIR / STTR GRANT OPPORTUNITIES

SBIR and STTR grant opportunities are also available for investigator-initiated ideas.  Companies are encouraged to review omnibus SBIR/STTR grant solicitations of the National Institutes of Health, Centers for Disease Control and Prevention and Food and Drug Administration posted on the NIH SBIR/STTR funding web page located at https://sbir.nih.gov/funding#omni-sbir.  Standard due dates for SBIR/STTR grant applications are September 5th, January 5th, and April 5th.  To understand better the differences between grants and contracts, see https://sbir.nih.gov/apply.  

For general information regarding the NIH/CDC SBIR Program, please refer to:

Office of Extramural Programs, Office of Extramural Research,

National Institutes of Health

Phone 301-435-2688

sbir@od.nih.gov